AR088048A1 - Señuelos notch1 humanos - Google Patents
Señuelos notch1 humanosInfo
- Publication number
- AR088048A1 AR088048A1 ARP120103557A ARP120103557A AR088048A1 AR 088048 A1 AR088048 A1 AR 088048A1 AR P120103557 A ARP120103557 A AR P120103557A AR P120103557 A ARP120103557 A AR P120103557A AR 088048 A1 AR088048 A1 AR 088048A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- repeat
- receptor protein
- terminal
- egf
- Prior art date
Links
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 102000045609 human NOTCH1 Human genes 0.000 abstract 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001759 Notch1 Receptor Human genes 0.000 abstract 1
- 108010029755 Notch1 Receptor Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Proteínas de fusión Notch1 que contienen un dominio extracelular de una proteína del receptor Notch1 humano y una porción Fc de un anticuerpo unido a la misma. El dominio extracelular (ECD) de la proteína del receptor Notch1 humano comienza con un aminoácido presente en el extremo N-terminal de la repetición 10 tipo EGF y se extiende al menos hasta un aminoácido C-terminal de la repetición 23 tipo EGF. La porción N-terminal del ECD de la proteína del receptor Notch1 humano se puede extender hasta un aminoácido C-terminal de la repetición 24 tipo EGF o se puede extender hasta un aminoácido C-terminal de la repetición 36 tipo EGF. También se provén composiciones de estas proteínas de fusión y métodos de tratamiento de degeneración macular relacionada con la edad (AMD), retinopatía diabética y cáncer usando las proteínas de fusión que se describen en la presente. Reivindicación 1: Una proteína de fusión, caracterizada porque comprende aminoácidos consecutivos que, comenzando por el extremo N-terminal de la proteína de fusión, corresponden a aminoácidos consecutivos presentes en: (a) un dominio extracelular de una proteína del receptor Notch1 humano, seguido por (b) una porción Fc de un anticuerpo, en donde el dominio extracelular de la proteína del receptor Notch1 humano (i) comienza con un aminoácido presente en el extremo N-terminal de la repetición 10 tipo EGF y (ii) se extiende por lo menos hasta un aminoácido C-terminal de la repetición 23 tipo EGF.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543186P | 2011-10-04 | 2011-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088048A1 true AR088048A1 (es) | 2014-05-07 |
Family
ID=48044136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103557A AR088048A1 (es) | 2011-10-04 | 2012-09-26 | Señuelos notch1 humanos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9738708B2 (es) |
| EP (1) | EP2763700A4 (es) |
| JP (1) | JP2014532061A (es) |
| KR (1) | KR20140093942A (es) |
| CN (1) | CN103917247A (es) |
| AR (1) | AR088048A1 (es) |
| AU (1) | AU2012318664A1 (es) |
| BR (1) | BR112014008025A2 (es) |
| CA (1) | CA2850944A1 (es) |
| CL (1) | CL2014000852A1 (es) |
| HK (1) | HK1198427A1 (es) |
| IL (1) | IL231920A0 (es) |
| MX (1) | MX2014004132A (es) |
| PE (1) | PE20141479A1 (es) |
| RU (1) | RU2014117160A (es) |
| SG (1) | SG11201401186RA (es) |
| TW (1) | TW201329105A (es) |
| WO (1) | WO2013052607A1 (es) |
| ZA (1) | ZA201403044B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111072A2 (en) | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| BRPI0815291A2 (pt) | 2007-08-23 | 2015-02-03 | Univ Columbia | "proteina de fusão, metodo de tratamento de pacientes que possuem um tumor, método de inibição da angiogênese em pacientes, método de tratamento de pacientes que possuem câncer do ovário, método de tratamento de pacientes que possuem um distúrbio metábolico, uso de proteína de fusão, método de inibição de linfoangiogênese patológica em pacientes, método de inibição da metástase de tumores em pacientes, método de inibição do crescimento de tumores secundários em pacientes, métodos de inibição da cooptação de vasos sanguineos por um tumor em pacientes, método de tratamento de cancer em pacientes e método de tratamento da retinopatia proliferativa vascular" |
| MX2011001805A (es) | 2008-08-22 | 2011-09-30 | Univ Columbia | Proteinas de fusion humanas basadas en notch3 como inhibidores de señuelo de la señalizacion de notch3. |
| TW201329105A (zh) * | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類ｎｏｔｃｈ１引誘物 |
| CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
| WO2017205651A1 (en) * | 2016-05-25 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling |
| WO2023192802A1 (en) * | 2022-04-01 | 2023-10-05 | The Board Of Trustees Of The University Of Illinois | Notch1 and notch4 decoys and methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE20030749A1 (en) * | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| FR2751986B1 (fr) | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
| US6379925B1 (en) | 1997-06-18 | 2002-04-30 | The Trustees Of Columbia University In The City Of New York | Angiogenic modulation by notch signal transduction |
| US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
| GB9927328D0 (en) | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| WO2003042246A2 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| EP1492816A2 (en) | 2002-04-05 | 2005-01-05 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
| AU2003255735A1 (en) | 2002-08-03 | 2004-02-23 | Lorantis Limited | Conjugate of notch signalling pathway modulators and their use in medical treatment |
| CA2497226A1 (en) | 2002-09-10 | 2004-03-25 | Lorantis Limited | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| WO2005111072A2 (en) | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| WO2006047878A1 (en) | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
| CN101277672A (zh) | 2005-07-29 | 2008-10-01 | 通用医疗公司 | 用于减少皮肤损伤的方法和组合物 |
| CA2666672A1 (en) | 2006-10-19 | 2008-05-02 | Genentech, Inc. | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases |
| AU2008209482B2 (en) * | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| BRPI0815291A2 (pt) | 2007-08-23 | 2015-02-03 | Univ Columbia | "proteina de fusão, metodo de tratamento de pacientes que possuem um tumor, método de inibição da angiogênese em pacientes, método de tratamento de pacientes que possuem câncer do ovário, método de tratamento de pacientes que possuem um distúrbio metábolico, uso de proteína de fusão, método de inibição de linfoangiogênese patológica em pacientes, método de inibição da metástase de tumores em pacientes, método de inibição do crescimento de tumores secundários em pacientes, métodos de inibição da cooptação de vasos sanguineos por um tumor em pacientes, método de tratamento de cancer em pacientes e método de tratamento da retinopatia proliferativa vascular" |
| ES2531541T3 (es) * | 2008-07-08 | 2015-03-17 | Oncomed Pharmaceuticals, Inc. | Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos |
| MX2011001805A (es) | 2008-08-22 | 2011-09-30 | Univ Columbia | Proteinas de fusion humanas basadas en notch3 como inhibidores de señuelo de la señalizacion de notch3. |
| TW201329105A (zh) * | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類ｎｏｔｃｈ１引誘物 |
-
2012
- 2012-09-26 TW TW101135396A patent/TW201329105A/zh unknown
- 2012-09-26 AR ARP120103557A patent/AR088048A1/es unknown
- 2012-10-04 WO PCT/US2012/058662 patent/WO2013052607A1/en active Application Filing
- 2012-10-04 CA CA2850944A patent/CA2850944A1/en not_active Abandoned
- 2012-10-04 EP EP12838379.1A patent/EP2763700A4/en not_active Withdrawn
- 2012-10-04 US US14/349,975 patent/US9738708B2/en active Active
- 2012-10-04 AU AU2012318664A patent/AU2012318664A1/en not_active Abandoned
- 2012-10-04 RU RU2014117160/10A patent/RU2014117160A/ru not_active Application Discontinuation
- 2012-10-04 CN CN201280054960.5A patent/CN103917247A/zh active Pending
- 2012-10-04 PE PE2014000473A patent/PE20141479A1/es not_active Application Discontinuation
- 2012-10-04 SG SG11201401186RA patent/SG11201401186RA/en unknown
- 2012-10-04 KR KR1020147012174A patent/KR20140093942A/ko not_active Application Discontinuation
- 2012-10-04 BR BR112014008025A patent/BR112014008025A2/pt not_active Application Discontinuation
- 2012-10-04 MX MX2014004132A patent/MX2014004132A/es unknown
- 2012-10-04 JP JP2014534677A patent/JP2014532061A/ja active Pending
-
2014
- 2014-04-03 IL IL231920A patent/IL231920A0/en unknown
- 2014-04-04 CL CL2014000852A patent/CL2014000852A1/es unknown
- 2014-04-25 ZA ZA2014/03044A patent/ZA201403044B/en unknown
- 2014-11-26 HK HK14111940.2A patent/HK1198427A1/xx unknown
-
2017
- 2017-07-05 US US15/641,712 patent/US10227399B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1198427A1 (en) | 2015-04-24 |
| US20170306006A1 (en) | 2017-10-26 |
| US9738708B2 (en) | 2017-08-22 |
| WO2013052607A9 (en) | 2014-04-10 |
| BR112014008025A2 (pt) | 2017-04-11 |
| CA2850944A1 (en) | 2013-04-11 |
| KR20140093942A (ko) | 2014-07-29 |
| JP2014532061A (ja) | 2014-12-04 |
| TW201329105A (zh) | 2013-07-16 |
| AU2012318664A1 (en) | 2014-05-22 |
| ZA201403044B (en) | 2016-01-27 |
| MX2014004132A (es) | 2014-07-24 |
| EP2763700A1 (en) | 2014-08-13 |
| US20140271643A1 (en) | 2014-09-18 |
| RU2014117160A (ru) | 2015-11-10 |
| IL231920A0 (en) | 2014-05-28 |
| US10227399B2 (en) | 2019-03-12 |
| SG11201401186RA (en) | 2014-04-28 |
| CL2014000852A1 (es) | 2014-12-12 |
| EP2763700A4 (en) | 2015-05-27 |
| CN103917247A (zh) | 2014-07-09 |
| WO2013052607A1 (en) | 2013-04-11 |
| PE20141479A1 (es) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088048A1 (es) | Señuelos notch1 humanos | |
| CY1124681T1 (el) | Διειδικα αντισωματα anti-vegf/anti-ang-2 και η χρηση τους στην αγωγη οφθαλμικων αγγειακων νοσων | |
| ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
| PE20161440A1 (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| SV2017005548A (es) | Proteinas de fusion | |
| PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
| CR20140047A (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
| PE20170142A1 (es) | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| CU20120116A7 (es) | Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5 | |
| CY1117695T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2 | |
| EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
| PE20142168A1 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| CL2016001405A1 (es) | A peptide mixture | |
| PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| GT201200058A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
| EA201592049A1 (ru) | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения | |
| GT201300149A (es) | Proteinas de union al tnf-a | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| UY33204A (es) | Metodos y composiciones usando polipeptidos de fusion de fgf23 | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |